Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.
Curr Gene Ther
; 8(3): 208-21, 2008 Jun.
Article
em En
| MEDLINE
| ID: mdl-18537595
ABSTRACT
Oncolytic HSV-1 has been developed as a novel anticancer agent. According to the properties and functions of HSV-1 encoded proteins, several genes have been targeted for engineering of oncolytic HSV-1. As a result, a variety of strategies have been applied to the engineering of oncolytic HSV-1. Success in cancer therapy for solid tumors requires a maximal oncolytic effect; however, recombinant HSV-1 that has been adapted to meet neurotoxicity requirements for the treatment of brain tumors may be too highly attenuated for effective use in solid tumors outside the brain. Recently, there has been renewed interest in the high potency of naturally oncolytic viruses. In this review, we will overview the engineered oncolytic HSV developed thus far, as well as its mechanism of selectivity and its mode of spreading within tumors. We also discuss the preclinical and clinical studies of HF-10, a non-engineered oncolytic HSV-1 virus, and its potential for use in cancer gene therapy.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Herpesvirus Humano 1
/
Terapia Viral Oncolítica
/
Neoplasias
Limite:
Animals
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Curr Gene Ther
Assunto da revista:
GENETICA MEDICA
/
TERAPEUTICA
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Japão